Company Analysis Catalent
1. Summary
Advantages
- The stock's return over the last year (25.93%) is higher than the sector average (-31.87%).
- The company's current efficiency (ROE=-25.32%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (63.48 $) is higher than fair price (61.88 $)
- Dividends (0%) are below the sector average (1.32%).
- Current debt level 50.43% has increased over 5 years from 47.85%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Catalent | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -2.2% | -1.4% |
| 90 days | 7.4% | -33.2% | 0.8% |
| 1 year | 25.9% | -31.9% | 21.5% |
CTLT vs Sector: Catalent has outperformed the "Healthcare" sector by 57.79% over the past year.
CTLT vs Market: Catalent has outperformed the market by 4.44% over the past year.
Stable price: CTLT is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CTLT with weekly volatility of 0.4986% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (63.48 $) is higher than the fair price (61.88 $).
Price is higher than fair: The current price (63.48 $) is 2.5% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (38.02) is lower than that of the sector as a whole (114.5).
P/E vs Market: The company's P/E (38.02) is lower than that of the market as a whole (70.26).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.84) is lower than that of the sector as a whole (9.44).
P/BV vs Market: The company's P/BV (2.84) is lower than that of the market as a whole (22.61).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.33) is lower than that of the sector as a whole (4.13).
P/S vs Market: The company's P/S indicator (2.33) is lower than that of the market as a whole (15.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-52.29) is lower than that of the sector as a whole (17.79).
EV/Ebitda vs Market: The company's EV/Ebitda (-52.29) is lower than that of the market as a whole (24.37).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -114.82% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-114.82%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-57.12%).
5.4. ROE
ROE vs Sector: The company's ROE (-25.32%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (-25.32%) is lower than that of the market as a whole (18.07%).
5.5. ROA
ROA vs Sector: The company's ROA (-10.16%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (-10.16%) is lower than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.45%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (7.45%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.32%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0.8016%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 18.10.2024 | Ferraro Joseph Anthony Officer |
Purchase | 59.97 | 19 190 | 320 |
| 16.10.2024 | Hawkeswood Thomas W Officer |
Purchase | 60.57 | 37 856 | 625 |
| 26.09.2024 | McErlane David Officer |
Purchase | 59.98 | 130 037 | 2 168 |
| 04.06.2024 | Hopson Ricky Pres. BioProduct Delivery, CoS |
Sale | 54.26 | 76 018 | 1 401 |
| 24.08.2023 | Fasman Steven L EVP & Chief Admin Officer |
Sale | 44.65 | 36 479 | 817 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
